FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine, including veterinary medicine, in particular to the serological diagnosis of infectious diseases common to humans and animals (COVID 19 is also of them). The essence of the group of inventions consists in using a diagnostic kit that includes all the necessary components for enzyme immunoassay, which provides detecting the SARS-CoV-2 virus in blood serum samples at an early stage of the disease with high specificity and sensitivity due to a fragment of the N SARS CoV 2 protein immobilized on the surface of microplate wells coated with albumin by silver nanoparticles. The group of inventions also relates to a method for detecting infection of humans and animals with SARS CoV2, implying the study of human and animal blood serums for the presence of antibodies to SARS CoV2 antigens immobilized on the surface of the EIA microplate, in the absence of antibodies to SARS CoV2, a person is considered to be in contact with this virus, in the case of detection of antibodies in an animal (cat) contacting only with its owner.
EFFECT: group of inventions provides sensitive and effective serological diagnostics of COVID-19 at the early stages of the disease development.
4 cl, 4 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| METHOD FOR CARRYING OUT AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR THE DETECTION OF ANTIBODIES IN A HUMAN BIOLOGICAL SAMPLE SPECIFIC TO THE SARS-COV2 HUMAN CORONAVIRUS, A TEST SYSTEM | 2021 |
|
RU2759149C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| POLYPEPTIDE MODULE FOR BINDING CONSERVATIVE EPITOPE OF RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 CORONAVIRUS | 2022 |
|
RU2809183C1 |
| STRAIN OF HYBRID ANIMAL CELLS MUS MUSCULUS 2E1B5 - PRODUCER OF A MONOCLONAL ANTIBODY AGAINST THE RECEPROT-BINDING DOMAIN OF PROTEIN S OF THE SARS-CoV-2 VIRUS | 2021 |
|
RU2771288C1 |
| STRAIN OF HYBRID ANIMAL CELLS Mus MUSCULUS 1F1 - PRODUCER OF A MONOCLONAL ANTIBODY AGAINST THE NUCLEOCAPSID PROTEIN N OF THE SARS-CoV-2 VIRUS | 2021 |
|
RU2769817C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| TEST SYSTEM AND METHOD FOR DIFFERENTIAL DETECTION OF ANTIBODIES TO SARS-COV-2 | 2021 |
|
RU2754340C1 |
| METHOD FOR DETERMINING THE SPECIFIC CELLULAR IMMUNE RESPONSE TO CORONAVIRUS ANTIGENS (SARS-CoV-2) | 2021 |
|
RU2780369C1 |
| THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN | 2022 |
|
RU2788359C1 |
